Adaptimmune Therapeutics PLC
adaptimmune.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 13, 2025. Its latest SEC filing is a RW from Apr 22, 2026.
10-Q for Q2 FY2025, filed Aug 13, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops personalized engineered T-cell treatments for people with solid-tumor cancers.
10-K for FY2024, filed Mar 24, 2025
How Did They Make Money?
Most revenue comes from collaborators funding clinical-trial work and license rights: some is paid upfront, trial funding is earned as the trial progresses, and option fees or royalties may follow. Treatment centers pay for TECELRA when it is delivered.
10-K for FY2024, filed Mar 24, 2025Under the terms of the agreement, the Company will receive initial payments of $100 million, comprising $70 million upfront and $30 million…View ↗
The Company expects to satisfy the POC Trial obligation over the period that the trial is completed, based on an estimate of the percentage…View ↗
Revenue from product sales is recognized at the point in time that the customer obtains control of the product, which is typically upon…View ↗
-
10-K for FY2024, filed Mar 24, 2025
FY2024 revenue by product or service ↗
$178M
-
10-K for FY2024, filed Mar 24, 2025
$178M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
|
0.7% |
Product revenue, net, FY2024
$1.2M Sources
|
Sold outright |
|
Development revenue
Mix
10-K for FY2024, filed Mar 24, 2025 |
99%
FY2021: 100%
|
Development revenue, FY2024
$176.8M Sources
|
Mix |
Who Were Their Customers?
Authorized Treatment Centers buy TECELRA directly; pharmaceutical collaborators contract with Adaptimmune for clinical-development and licensing work.
10-K for FY2024, filed Mar 24, 2025The Company generates revenue from sales of its commercially approved T-cell therapy. As of December 31, 2024, the Company’s only…View ↗
The Company generates development revenue from collaboration agreements with customers. The Company had three development…View ↗
On May 30, 2024, the Company entered into the Galapagos Collaboration Agreement, a clinical collaboration agreement with Galapagos. The…View ↗
Did Revenues Turn Into Profits?
No. It lost $70.8M in FY2024.
10-K for FY2024, filed Mar 24, 2025
−$68.8MView ↗
10-K for FY2024, filed Mar 24, 2025
−$70.8MView ↗
10-K for FY2024, filed Mar 24, 2025
−$74.1MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 13, 2025
−$30.3MView ↗
- ▼ Now a loss
- vs $69.5M in Q2 FY2024
10-Q for Q2 FY2025, filed Aug 13, 2025
Open tableView ↗
-
Oct 20, 2025
Company announces voluntary Nasdaq delisting
It plans to deregister its ADSs and expects trading to move to the OTC Pink Limited Market.
Sources
8-K, filed Oct 20, 2025
On October 16, 2025, Adaptimmune Therapeutics plc (the “Company”) notified The Nasdaq Stock Market, LLC, pursuant to authorization by its…View ↗
-
Sep 8, 2025
Christopher Hill appointed chief financial officer
His appointment as CFO took effect on September 10, 2025.
Sources
8-K, filed Sep 8, 2025
On September 6, 2025, Adaptimmune Limited, a subsidiary of Adaptimmune Therapeutics plc (the “Company”), entered into a consulting…View ↗
-
Aug 29, 2025
Gavin Wood's employment as CFO ends
His employment ended by reason of redundancy on September 9, 2025.
Sources
8-K, filed Aug 29, 2025
As previously disclosed, on December 18, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a letter agreement with Gavin Wood…View ↗
-
Aug 13, 2025
Transfers cell therapy assets to US WorldMeds
The transaction covered TECELRA, lete-cel, afami-cel and uza-cel for $55 million upfront, with up to $30 million in future milestone payments.
Sources
8-K, filed Aug 13, 2025
Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55…View ↗
Grew. Revenue grew 45.0x in 4 years, from $4M in FY2020 to $178M in FY2024, about 159% a year.
Afami-cel reaches commercialization
The earlier report described afami-cel in trials and a possible future launch; the latest describes TECELRA as approved and in commercialization.
10-K for FY2021, filed Mar 14, 2022 10-K for FY2024, filed Mar 24, 2025SPEARHEAD-1 Phase 2 Trial with afami-cel (ADP-A2M4): A registration directed Phase 2 clinical trial is ongoing in synovial sarcoma in which…View ↗
A narrower development focus
The earlier report described a broad pipeline of cell therapy approaches; the latest prioritizes its sarcoma franchise and focuses preclinical development on selected programs.
10-K for FY2021, filed Mar 14, 2022 10-K for FY2024, filed Mar 24, 2025Our proprietary platform enables us to identify cancer targets, find and develop cell therapy candidates active against those targets and…View ↗
Outside of the MAGE-A4 franchise, we have an active preclinical pipeline of cell therapy candidates with the aim of delivering five new…View ↗
We are also developing allogeneic or “off-the-shelf” cell therapies utilizing a proprietary allogeneic platform. The platform utilizes…View ↗
During the fourth quarter of 2024 we announced that we were ceasing further investment in all non-core programs. We are undertaking a…View ↗
We have two preclinical programs for the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). We have…View ↗
Building a commercial franchise in synovial sarcoma and myxoid liposarcoma. Our first T-cell therapy product, TECELRA, is now approved in…View ↗
Collaboration partners change
The earlier report described collaborations with Astellas, Genentech and GSK; the latest describes a clinical collaboration with Galapagos and says prior Genentech and GSK collaborations ended.
10-K for FY2021, filed Mar 14, 2022 10-K for FY2024, filed Mar 24, 2025We have strategic collaborations in place with Astellas and Genentech Inc (“Genentech”):View ↗
During Q3 2021 we announced a strategic collaboration with Genentech and F. Hoffman-La Roche Ltd.to research, develop, and commercialize…View ↗
We also have a strategic collaboration program ongoing with Astellas (through its wholly-owned subsidiary Universal Cells) in relation to…View ↗
We also have several development and research collaborations including our collaboration with GSK for the development, manufacture and…View ↗
Who Did They Compete With?
Competes with Iovance, Immatics, Allogene Therapeutics, Fate Therapeutics, and Atara Bio
10-K for FY2024, filed Mar 24, 2025From other autologous cell therapies: There are a number of other cell therapies that have already received marketing approval or are…View ↗
Loading...
